We are analyzing https://link.springer.com/article/10.1007/s13402-016-0268-6.

Title:
PSA and beyond: alternative prostate cancer biomarkers | Cellular Oncology
Description:
The use of biomarkers for prostate cancer screening, diagnosis and prognosis has the potential to improve the clinical management of the patients. Owing to inherent limitations of the biomarker prostate-specific antigen (PSA), intensive efforts are currently directed towards a search for alternative prostate cancer biomarkers, particularly those that can predict disease aggressiveness and drive better treatment decisions. A literature search of Medline articles focused on recent and emerging advances in prostate cancer biomarkers was performed. The most promising biomarkers that have the potential to meet the unmet clinical needs in prostate cancer patient management and/or that are clinically implemented were selected. With the advent of advanced genomic and proteomic technologies, we have in recent years seen an enormous spurt in prostate cancer biomarker research with several promising alternative biomarkers being discovered that show an improved sensitivity and specificity over PSA. The new generation of biomarkers can be tested via serum, urine, or tissue-based assays that have either received regulatory approval by the US Food and Drug Administration or are available as Clinical Laboratory Improvement Amendments-based laboratory developed tests. Additional emerging novel biomarkers for prostate cancer, including circulating tumor cells, microRNAs and exosomes, are still in their infancy. Together, these biomarkers provide actionable guidance for prostate cancer risk assessment, and are expected to lead to an era of personalized medicine.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Business & Finance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

cancer, pubmed, prostate, google, scholar, article, cas, biomarkers, central, psa, urol, res, clinical, antigen, clin, prostatic, prostatespecific, oncol, detection, biomarker, risk, patients, circulating, eur, men, cell, microrna, saini, screening, serum, tumor, role, prognostic, early, int, research, search, genomic, urine, micrornas, prospective, propsa, urology, study, pca, assay, progression, privacy, cookies, content,

Topics {✒️}

formalin-fixed paraffin-embedded samples month download article/chapter stable blood-based markers alpha-methylacyl-coa racemase pubmed google scholar plasma-derived exosomal survivin castration-resistant prostate cancer alternative prostate cancer biomarkers fusion-negative prostate cancer free prostate-specific antigen total prostate-specific antigen biomarker prostate-specific antigen national cancer institute benign prostatic disease pten-deficient prostate cancer erg-positive prostate cancer benign prostate examination full article pdf prostatic specific antigen prognostic urinary biomarkers prostate cancer surveillance sharanjot saini ph circulating tumor cells privacy choices/manage cookies tmprss2-erg gene fusions alpha-methylacyl coenzyme molecularly-based therapeutics prostatic acid phosphatase google scholar tissue-based assays promising alternative biomarkers prostate-specific gene prostate-specific antigen prostate needle biopsies primary prostate cancer related subjects prognostic microrna signatures american cancer society biopsy sampling error serum isoform [-2]propsa promising plasma biomarkers erg fusion-positive prostate cancer biomarkers prostate cancer progression multicentre european study european randomized study decide study group grant number ro1ca177984 molecular urine assay contemporary prostatectomy cohort

Questions {❓}

Chan, Biomarkers in prostate cancer: what’s new?
Dolo, Extracellular vesicles in prostate cancer: new future clinical strategies?
Paparel, Urinary prostate cancer 3 test: toward the age of reason?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:PSA and beyond: alternative prostate cancer biomarkers
         description:The use of biomarkers for prostate cancer screening, diagnosis and prognosis has the potential to improve the clinical management of the patients. Owing to inherent limitations of the biomarker prostate-specific antigen (PSA), intensive efforts are currently directed towards a search for alternative prostate cancer biomarkers, particularly those that can predict disease aggressiveness and drive better treatment decisions. A literature search of Medline articles focused on recent and emerging advances in prostate cancer biomarkers was performed. The most promising biomarkers that have the potential to meet the unmet clinical needs in prostate cancer patient management and/or that are clinically implemented were selected. With the advent of advanced genomic and proteomic technologies, we have in recent years seen an enormous spurt in prostate cancer biomarker research with several promising alternative biomarkers being discovered that show an improved sensitivity and specificity over PSA. The new generation of biomarkers can be tested via serum, urine, or tissue-based assays that have either received regulatory approval by the US Food and Drug Administration or are available as Clinical Laboratory Improvement Amendments-based laboratory developed tests. Additional emerging novel biomarkers for prostate cancer, including circulating tumor cells, microRNAs and exosomes, are still in their infancy. Together, these biomarkers provide actionable guidance for prostate cancer risk assessment, and are expected to lead to an era of personalized medicine.
         datePublished:2016-01-20T00:00:00Z
         dateModified:2016-01-20T00:00:00Z
         pageStart:97
         pageEnd:106
         sameAs:https://doi.org/10.1007/s13402-016-0268-6
         keywords:
            Prostate cancer
            Biomarkers
            Prognostic
            Predictive
            Diagnostic
            Cancer Research
            Biomedicine
            general
            Pathology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13402-016-0268-6/MediaObjects/13402_2016_268_Fig1_HTML.gif
         isPartOf:
            name:Cellular Oncology
            issn:
               2211-3436
               2211-3428
            volumeNumber:39
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Sharanjot Saini
               affiliation:
                     name:Veterans Affairs Medical Center
                     address:
                        name:Department of Urology, Urology Research (112J), Veterans Affairs Medical Center, San Francisco, USA
                        type:PostalAddress
                     type:Organization
                     name:University of California San Francisco
                     address:
                        name:University of California San Francisco, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:PSA and beyond: alternative prostate cancer biomarkers
      description:The use of biomarkers for prostate cancer screening, diagnosis and prognosis has the potential to improve the clinical management of the patients. Owing to inherent limitations of the biomarker prostate-specific antigen (PSA), intensive efforts are currently directed towards a search for alternative prostate cancer biomarkers, particularly those that can predict disease aggressiveness and drive better treatment decisions. A literature search of Medline articles focused on recent and emerging advances in prostate cancer biomarkers was performed. The most promising biomarkers that have the potential to meet the unmet clinical needs in prostate cancer patient management and/or that are clinically implemented were selected. With the advent of advanced genomic and proteomic technologies, we have in recent years seen an enormous spurt in prostate cancer biomarker research with several promising alternative biomarkers being discovered that show an improved sensitivity and specificity over PSA. The new generation of biomarkers can be tested via serum, urine, or tissue-based assays that have either received regulatory approval by the US Food and Drug Administration or are available as Clinical Laboratory Improvement Amendments-based laboratory developed tests. Additional emerging novel biomarkers for prostate cancer, including circulating tumor cells, microRNAs and exosomes, are still in their infancy. Together, these biomarkers provide actionable guidance for prostate cancer risk assessment, and are expected to lead to an era of personalized medicine.
      datePublished:2016-01-20T00:00:00Z
      dateModified:2016-01-20T00:00:00Z
      pageStart:97
      pageEnd:106
      sameAs:https://doi.org/10.1007/s13402-016-0268-6
      keywords:
         Prostate cancer
         Biomarkers
         Prognostic
         Predictive
         Diagnostic
         Cancer Research
         Biomedicine
         general
         Pathology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13402-016-0268-6/MediaObjects/13402_2016_268_Fig1_HTML.gif
      isPartOf:
         name:Cellular Oncology
         issn:
            2211-3436
            2211-3428
         volumeNumber:39
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Sharanjot Saini
            affiliation:
                  name:Veterans Affairs Medical Center
                  address:
                     name:Department of Urology, Urology Research (112J), Veterans Affairs Medical Center, San Francisco, USA
                     type:PostalAddress
                  type:Organization
                  name:University of California San Francisco
                  address:
                     name:University of California San Francisco, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cellular Oncology
      issn:
         2211-3436
         2211-3428
      volumeNumber:39
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Veterans Affairs Medical Center
      address:
         name:Department of Urology, Urology Research (112J), Veterans Affairs Medical Center, San Francisco, USA
         type:PostalAddress
      name:University of California San Francisco
      address:
         name:University of California San Francisco, San Francisco, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Sharanjot Saini
      affiliation:
            name:Veterans Affairs Medical Center
            address:
               name:Department of Urology, Urology Research (112J), Veterans Affairs Medical Center, San Francisco, USA
               type:PostalAddress
            type:Organization
            name:University of California San Francisco
            address:
               name:University of California San Francisco, San Francisco, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Urology, Urology Research (112J), Veterans Affairs Medical Center, San Francisco, USA
      name:University of California San Francisco, San Francisco, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(331)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.78s.

LINK . SPRINGER . COM {}